ArticleLeukemia2003
Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B.
Article in Leukemia, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 66 citations in OpenAlex.
- Beyond Integrin Activation: Kindlin-3 as an Organiser of Immune Receptor Signalling.International journal of molecular sciences · 2026Review
- A frameshift variant in FAM129C contributes to achalasia through B cell responses against the GABANature communications · 2026Article
- Review
- Review
- Structural Insight on Functional Regulation of Human MINERVA Protein.International journal of molecular sciences · 2020Article
- Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia.Saudi medical journal · 2019Review
- Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia.Molecular & cellular proteomics : MCP · 2018Article
- Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.Scientific reports · 2017Article
- The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.Journal of cellular and molecular medicine · 2017Article
- Structure and lipid-binding properties of the kindlin-3 pleckstrin homology domain.The Biochemical journal · 2017Article
- Targetable genetic features of primary testicular and primary central nervous system lymphomas.Blood · 2016Article
- Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems.American journal of cancer research · 2016Article
- Biophysical analysis of Kindlin-3 reveals an elongated conformation and maps integrin binding to the membrane-distal β-subunit NPXY motif.The Journal of biological chemistry · 2012Article
- A molecular mechanism for the requirement of PAT-4 (integrin-linked kinase (ILK)) for the localization of UNC-112 (Kindlin) to integrin adhesion sites.The Journal of biological chemistry · 2012Article
- Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease.Journal of clinical bioinformatics · 2012Article
- FAM129B/MINERVA, a novel adherens junction-associated protein, suppresses apoptosis in HeLa cells.The Journal of biological chemistry · 2011Article
- Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.PloS one · 2010Article
- Transcriptional profiling of hypothalamus during development of adiposity in genetically selected fat and lean chickens.Physiological genomics · 2010Article
- Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.Molecular & cellular proteomics : MCP · 2009Article
- Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects.The Journal of biological chemistry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell-specific plasma-membrane proteins are potential targets for either small molecule or antibody-based therapies. We have sought to annotate proteins expressed at the cell surface membrane in patients with chronic lymphocytic leukemia (CLL) using plasma-membrane-based proteomic analysis to identify previously uncharacterized and potentially B-cell-specific proteins. Proteins from plasma-membrane fractions were separated on one-dimensional gels and trypsinized fractions subjected to high-throughput MALDI-TOF mass spectrometry. Using this method, many known B-cell surface antigens were detected, but also known proteins not previously described in this disease or in this cellular compartment, including cell surface receptors, membrane-associated enzymes and secreted proteins, and completely unknown proteins. To validate the method, we show that BLK, a B-cell-specific kinase, is located in the CLL-plasma-membrane fraction. We also describe two novel proteins (MIG2B and B-cell novel protein #1, BCNP1), which are expressed preferentially in B cells. MIG2B is in a highly conserved and defined gene family containing two plasma-membrane-binding ezrin/radixin/moesin domains and a pleckstrin homology domain; the Caenorhabditis elegans homolog (UNC-112) is a membrane-associated protein that colocalizes with integrin at cell-matrix adhesion complexes. BCNP1 is a completely unknown protein with three predicted transmembrane domains, with three alternatively spliced final exons. Proteomic analysis may thus define new potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.